Regulation - Pricing, Gastro-intestinals

Filter

Current filters:

PricingGastro-intestinals

Popular Filters

IQWiG finds no added benefit proven for Constella in IBS

07-08-2013

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

AlmirallConstellaEuropeGastro-intestinalsIronwood PharmaceuticalsPharmaceuticalPricingRegulation

AstraZeneca’s blood thinner Brilinta/Brilique demonstrates cost effectiveness; new Nexium indication filed in Japan

24-10-2011

Data from eight countries shows that using Anglo-Swedish drug major AstraZeneca’s (LSE: AZN) Brilique/Brilinta…

AstraZenecaBrilintaBriliqueCardio-vascularDaiichi SankyoGastro-intestinalsNexiumPharmaceuticalPricingRegulation

Back to top